Algert Global LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)

Algert Global LLC purchased a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 24,472 shares of the company's stock, valued at approximately $1,112,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in Janux Therapeutics by 38.6% during the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company's stock worth $51,127,000 after purchasing an additional 378,477 shares in the last quarter. Logos Global Management LP increased its stake in Janux Therapeutics by 400.0% during the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company's stock worth $31,418,000 after purchasing an additional 600,000 shares in the last quarter. Samlyn Capital LLC boosted its position in Janux Therapeutics by 9.6% during the 2nd quarter. Samlyn Capital LLC now owns 324,703 shares of the company's stock worth $13,602,000 after acquiring an additional 28,312 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Janux Therapeutics by 202.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company's stock worth $10,639,000 after acquiring an additional 156,675 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in Janux Therapeutics during the 2nd quarter worth approximately $5,715,000. 75.39% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. UBS Group assumed coverage on Janux Therapeutics in a research report on Thursday, October 24th. They set a "buy" rating and a $69.00 price target for the company. Leerink Partnrs raised Janux Therapeutics to a "strong-buy" rating in a research report on Friday, November 22nd. Stifel Nicolaus initiated coverage on Janux Therapeutics in a research report on Friday, September 6th. They set a "buy" rating and a $70.00 price target for the company. William Blair reissued an "outperform" rating on shares of Janux Therapeutics in a report on Thursday, November 14th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $100.00 price objective on shares of Janux Therapeutics in a report on Thursday, November 7th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $67.70.

Janux Therapeutics Trading Down 2.5 %

JANX stock traded down $1.18 during trading hours on Friday, hitting $45.21. 534,619 shares of the stock were exchanged, compared to its average volume of 709,527. The firm has a market capitalization of $2.37 billion, a P/E ratio of -38.64 and a beta of 3.52. The company has a 50-day simple moving average of $49.81 and a two-hundred day simple moving average of $45.80. Janux Therapeutics, Inc. has a 12 month low of $7.79 and a 12 month high of $65.60.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. The company's revenue for the quarter was down 82.6% on a year-over-year basis. On average, equities research analysts predict that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Insider Activity

In related news, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $51.60, for a total value of $1,290,000.00. Following the transaction, the chief executive officer now directly owns 257,054 shares of the company's stock, valued at $13,263,986.40. The trade was a 8.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew Hollman Meyer sold 50,000 shares of Janux Therapeutics stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $45.96, for a total value of $2,298,000.00. Following the completion of the transaction, the insider now directly owns 67,592 shares in the company, valued at approximately $3,106,528.32. This represents a 42.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 445,610 shares of company stock valued at $20,578,666. 29.40% of the stock is currently owned by corporate insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.